Real-world data and recommended dosage of non-Vitamin K oral anticoagulants for Korean patients

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation (AF). The results of the trials showed that all NOACs were at least non-inferior to warfarin in the prevention of stroke/thromboembolism and showed lower rates of intracranial bleeding than those associated with warfarin. However, the trials were designed differently, varied in the inclusion/exclusion criteria, and used either one dose or a low/high dose of the NOAC drug. Some of these differences have challenged the ability to directly compare various NOACs, and comparative data on effectiveness and intracranial bleeding are sparse in "real-world" patients. Real-world data complement data from large randomized phase III trials by providing new aspects of the "real-world" absolute risks of ischemic and hemorrhagic stroke associated with NOACs vs. warfarin. Moreover, "real-world" fragile patients might have been included (e.g., patients with increased risk of bleeding, liver disease, and chronic kidney disease), although these patients would be less represented in trials. This paper introduces recently published real-world data of NOACs and further suggests the recommended dosage of NOACs for Korean patients.

Original languageEnglish
Pages (from-to)833-841
Number of pages9
JournalKorean Circulation Journal
Volume47
Issue number6
DOIs
Publication statusPublished - 2017 Nov

Fingerprint

Anticoagulants
Warfarin
Hemorrhage
Stroke
Thromboembolism
Chronic Renal Insufficiency
Atrial Fibrillation
Liver Diseases

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{042b139ab9a24c12b5306bf8d0b8c451,
title = "Real-world data and recommended dosage of non-Vitamin K oral anticoagulants for Korean patients",
abstract = "Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation (AF). The results of the trials showed that all NOACs were at least non-inferior to warfarin in the prevention of stroke/thromboembolism and showed lower rates of intracranial bleeding than those associated with warfarin. However, the trials were designed differently, varied in the inclusion/exclusion criteria, and used either one dose or a low/high dose of the NOAC drug. Some of these differences have challenged the ability to directly compare various NOACs, and comparative data on effectiveness and intracranial bleeding are sparse in {"}real-world{"} patients. Real-world data complement data from large randomized phase III trials by providing new aspects of the {"}real-world{"} absolute risks of ischemic and hemorrhagic stroke associated with NOACs vs. warfarin. Moreover, {"}real-world{"} fragile patients might have been included (e.g., patients with increased risk of bleeding, liver disease, and chronic kidney disease), although these patients would be less represented in trials. This paper introduces recently published real-world data of NOACs and further suggests the recommended dosage of NOACs for Korean patients.",
author = "Boyoung Joung",
year = "2017",
month = "11",
doi = "10.4070/kcj.2017.0158",
language = "English",
volume = "47",
pages = "833--841",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "6",

}

Real-world data and recommended dosage of non-Vitamin K oral anticoagulants for Korean patients. / Joung, Boyoung.

In: Korean Circulation Journal, Vol. 47, No. 6, 11.2017, p. 833-841.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Real-world data and recommended dosage of non-Vitamin K oral anticoagulants for Korean patients

AU - Joung, Boyoung

PY - 2017/11

Y1 - 2017/11

N2 - Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation (AF). The results of the trials showed that all NOACs were at least non-inferior to warfarin in the prevention of stroke/thromboembolism and showed lower rates of intracranial bleeding than those associated with warfarin. However, the trials were designed differently, varied in the inclusion/exclusion criteria, and used either one dose or a low/high dose of the NOAC drug. Some of these differences have challenged the ability to directly compare various NOACs, and comparative data on effectiveness and intracranial bleeding are sparse in "real-world" patients. Real-world data complement data from large randomized phase III trials by providing new aspects of the "real-world" absolute risks of ischemic and hemorrhagic stroke associated with NOACs vs. warfarin. Moreover, "real-world" fragile patients might have been included (e.g., patients with increased risk of bleeding, liver disease, and chronic kidney disease), although these patients would be less represented in trials. This paper introduces recently published real-world data of NOACs and further suggests the recommended dosage of NOACs for Korean patients.

AB - Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation (AF). The results of the trials showed that all NOACs were at least non-inferior to warfarin in the prevention of stroke/thromboembolism and showed lower rates of intracranial bleeding than those associated with warfarin. However, the trials were designed differently, varied in the inclusion/exclusion criteria, and used either one dose or a low/high dose of the NOAC drug. Some of these differences have challenged the ability to directly compare various NOACs, and comparative data on effectiveness and intracranial bleeding are sparse in "real-world" patients. Real-world data complement data from large randomized phase III trials by providing new aspects of the "real-world" absolute risks of ischemic and hemorrhagic stroke associated with NOACs vs. warfarin. Moreover, "real-world" fragile patients might have been included (e.g., patients with increased risk of bleeding, liver disease, and chronic kidney disease), although these patients would be less represented in trials. This paper introduces recently published real-world data of NOACs and further suggests the recommended dosage of NOACs for Korean patients.

UR - http://www.scopus.com/inward/record.url?scp=85039863456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039863456&partnerID=8YFLogxK

U2 - 10.4070/kcj.2017.0158

DO - 10.4070/kcj.2017.0158

M3 - Review article

AN - SCOPUS:85039863456

VL - 47

SP - 833

EP - 841

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 6

ER -